FDA approves Sanofi's Dupixent for COPD. Eli Lilly is set to invest $4.5 billion to build a new manufacturing and research ...

The "Chronic Urticaria: Competitive Landscape" report has been added tAndMarkets.com's offering.This report provides a data-driven overview of the current and future competitive landscape in chronic ...

Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes ...

On Tuesday night, October 1st, at a gala event held at Gotham Hall in New York City, PM360 announced the winners of its 16th annual Trailblazer Awards. In total, PM360, a leading life sciences ...

Real-world outcomes of patients with relapsed/refractory multiple myeloma treated with the chimeric antigen receptor (CAR) ...

Sanofi (SNY) sells global rights to Enjaymo treatment for cold agglutinin disease to Recordati (RCDTF) in a deal worth up to ...

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Sanofi is paying $175 million upfront to claim a share of an experimental vaccine developed by Johnson & Johnson’s pharma unit Janssen that aims to tackle a major cause of blood infections.

External affairs minister S Jaishankar meets with Sajith Premadasa, Sri Lanka's opposition leader, during his visit to Colombo. Jaishankar is the first foreign dignitary to visit since the NPP ...

Blasts Shake Beirut as Israel Targets Hezbollah Leaders, Officials Say Israeli officials said planes bombed a bunker where senior Hezbollah officials were meeting, including the presumed successor ...

The decision would reopen ports on the East and Gulf Coasts, easing worries that the strike would burden the economy five weeks before the election. 5 min read 3 Ex-Officers Acquitted of Most ...